First large-scale study reinforces need to fund and expand simplified HIV programs that
deliver significant, life-saving health benefits in resource-challenged settings
Vancouver, BC (July 18, 2011) - A landmark study by the BC Centre for Excellence in HIV/AIDS (BC-CfE),
the University of Ottawa, and the University of British Columbia (UBC) shows that patients in Africa receiving combination antiretroviral
therapy (cART) for HIV can expect to live a near normal lifespan.
The study, published today in the prestigious Annals of Internal Medicine, is the first large-scale analysis
of life expectancy outcomes in Africa for HIV patients on cART and shows significant variance between patient subgroups. Females have a
significantly higher life expectancy than men, and in all participants, early initiation of treatment was associated with longer life
"The substantial life expectancy afforded by widespread access to cART underscores the fact that HIV
diagnosis and treatment in resource-limited settings should no longer be considered a death sentence," said principal investigator
Dr. Edward Mills, associate researcher at the BC-CfE and Canada Research Chair in Global Health at University of Ottawa. "Instead,
HIV-infected people should plan and prepare for a long and fulfilling life."
The authors believe that the study, conducted in Uganda, reflects the situation in many other settings in Africa, where
simplified HIV/AIDS care in rural, semi-rural and urban settings is available.
"Our findings are further evidence that the global investment in HIV and AIDS programming is clearly working," said
Dr. Mark Dybul, a study author who led the implementation of the multibillion-dollar U.S. President's Emergency Plan for AIDS Relief
(PEPFAR) from 2006-2009 and is now at Georgetown University and the George W. Bush Institute. "Healthcare organizations - even
in resource-poor settings - are providing services and therapies that offer important, life-saving benefits to people suffering
The study analyzed a cohort of 22,315 individuals aged 14 or older, who initiated cART at The AIDS Support Organization (TASO)
clinics between 2000 and 2009. In Uganda, life expectancy at birth is approximately 55 years and increases as individuals survive key
milestones. Life expectancy at age 20 years for the overall study cohort on cART was an additional 26.7 years and at age 35 an
additional 27.9 years.
Males showed consistently lower life expectancy than females. Life expectancy at age 20 years was 19.1 years for males and
30.6 years for females, and at age 35 years was 22 years for males and 32.5 years for females. Men typically access care at a later
stage, with more advanced disease, and have higher rates of mortality than females. "Men remain one of our huge challenges in
terms of access to clinical services," said Mills.
The study found a strong association between baseline CD4 cell status and mortality when controlling for factors such as
age, year of cART initiation and gender. Those who started cART earlier, at a higher CD4 cell status, lived longer.
"These benefits will only be sustained if there is continued support for cART scale up by the international donor
community and national governments," said study author Dr. Jean Nachega, Professor of Medicine and director of the Centre for
Infectious Diseases at Stellenbosch University, Cape Town, South Africa. "We require sustainable investment and simplified
treatment options to deliver long-term care and access more people in Africa with HIV."
Although more than 200,000 patients are receiving cART in Uganda, about 200,000 more Ugandans await cART initiation.
The study findings also support the Treatment as Prevention strategy pioneered at the BC-CfE and adopted by the Joint United
Nations Programme on HIV/AIDS (UNAIDS) as a key pillar of its Treatment 2.0 initiative, the cornerstone of the so called "Prevention
Revolution." Treatment as Prevention calls for widespread HIV testing and early treatment for all medically eligible individuals to
prevent disease progression and death and to prevent HIV transmission. Treatment as Prevention could be an effective component
of combination prevention strategies.
The study was funded by the Canadian Institutes of Health Research (CIHR). "For years, a diagnosis of HIV was viewed
as a death sentence. This new discovery will change that view for many people in the world. CIHR extends their congratulations to
Dr. Mills and his team. I am optimistic that these findings will provide a promising future for those who suffer from HIV", said
Dr. Marc Ouellette, scientific director of the CIHR Institute of Infection and Immunity.
Full copy of the study Life Expectancy of Persons Receiving Combination Antiretroviral Therapy in Low-Income
Countries: A Cohort Analysis From Uganda , is at: http://www.annals.org/content/early/2011/07/18/0003-4819-155-4-201108160-00358 .
And the related editorial Life Expectancy in Africa: Back to the Future? by Dr. Deborah Cotton, deputy editor of the Annals of Internal Medicine, can be found at: http://www.annals.org/content/early/2011/07/18/0003-4819-155-4-201108160-00359 .
About the B.C. Centre for Excellence in HIV/AIDS:
The BC Centre for Excellence in HIV/AIDS (BC-CfE) is Canada's largest HIV/AIDS research, treatment and education facility and is internationally recognized as an innovative world leader in combating HIV/AIDS and related diseases. It is based at St. Paul's Hospital, Providence Health Care, a teaching hospital of the University of British Columbia. The BC-CfE works in close collaboration with key provincial stakeholders, including Health Authorities, health care providers, academics from other institutions, and the community to improve the health of British Columbians living with HIV through developing, monitoring and disseminating comprehensive research and treatment programs for HIV and related illnesses.
Starting in the early 2000s, the BC-CfE-pioneered the "Treatment as Prevention" strategy, which promotes increased testing and facilitated access to antiretroviral treatment for all medically eligible HIV-positive people in order to stop the progression of HIV infection to AIDS or death, and simultaneously halt the spread of HIV and AIDS. Treatment as Prevention is recognized and supported internationally by organizations including the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization (WHO). Additionally, China has implemented a national HIV and AIDS policy based on the BC-CfE's Treatment as Prevention strategy.
In February 2010, theB.C. government funded and launched a $48-million pilot project called Seek and Treat for Optimal Prevention of HIV/AIDS (STOP HIV/AIDS) to further capitalize on the early gains associated with the BC-CfE's Treatment as Prevention strategy. Led by the BC-CfE, this four-year initiative will be implemented in collaboration with provincial stakeholders to improve access to HIV testing, treatment, and support services in designated areas within British Columbia. www.cfenet.ubc.ca
About the Canadian Institutes of Health Research (CIHR)
The Canadian Institutes of Health Research (CIHR) is the Government of Canada's agency for health research. CIHR's mission is to create new scientific knowledge and to enable its translation into improved health, more effective health services and products, and a strengthened Canadian health-care system. Composed of 13 Institutes, CIHR provides leadership and support to more than 13,600 health researchers and trainees across Canada. www.cihr-irsc.gc.ca .
"Reproduced with permission - BC Centre for Excellence in HIV/AIDS (BC-CfE)"
BC Centre for Excellence in HIV/AIDS (BC-CfE)